GLIPR2 and ovarian cancer: These endeavors elucidated an augmented GLIPR2 expression in BLCA, BRCA, cholangiocarcinoma (CHOL), amongst others, in contrast to a diminution in breast, colon, ovarian cancers, among others (Figures 2E, F).